Cabaletta Bio, Inc. $CABA Holdings Lifted by Bain Capital Life Sciences Investors LLC

Bain Capital Life Sciences Investors LLC increased its position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA) by 250.5% during the second quarter, Holdings Channel.com reports. The fund owned 9,677,125 shares of the company’s stock after acquiring an additional 6,916,237 shares during the quarter. Cabaletta Bio accounts for approximately 1.8% of Bain Capital Life Sciences Investors LLC’s investment portfolio, making the stock its 12th largest position. Bain Capital Life Sciences Investors LLC owned 0.19% of Cabaletta Bio worth $14,709,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. boosted its position in shares of Cabaletta Bio by 142.9% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,829,758 shares of the company’s stock valued at $13,421,000 after purchasing an additional 5,195,285 shares in the last quarter. Marshall Wace LLP lifted its stake in Cabaletta Bio by 470.7% during the second quarter. Marshall Wace LLP now owns 190,957 shares of the company’s stock valued at $290,000 after purchasing an additional 157,497 shares during the last quarter. Invesco Ltd. boosted its holdings in Cabaletta Bio by 37.5% during the second quarter. Invesco Ltd. now owns 84,831 shares of the company’s stock worth $129,000 after buying an additional 23,156 shares in the last quarter. XTX Topco Ltd bought a new stake in Cabaletta Bio during the second quarter worth approximately $148,000. Finally, Jefferies Financial Group Inc. acquired a new position in Cabaletta Bio in the second quarter worth approximately $3,036,000.

Cabaletta Bio Price Performance

Shares of NASDAQ:CABA opened at $2.36 on Friday. The company’s fifty day moving average is $2.52 and its two-hundred day moving average is $2.04. The company has a market cap of $227.19 million, a P/E ratio of -0.93 and a beta of 3.17. Cabaletta Bio, Inc. has a 12-month low of $0.99 and a 12-month high of $3.67.

Cabaletta Bio (NASDAQ:CABA) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.05. Equities research analysts anticipate that Cabaletta Bio, Inc. will post -2.34 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Jefferies Financial Group started coverage on Cabaletta Bio in a research report on Friday, October 10th. They set a “buy” rating and a $14.00 price objective for the company. Cantor Fitzgerald boosted their target price on Cabaletta Bio from $15.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cabaletta Bio in a research report on Wednesday, October 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Cabaletta Bio in a research note on Friday, October 10th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Cabaletta Bio has an average rating of “Moderate Buy” and a consensus target price of $15.11.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.